Figure 6
Effects of hSCR18–20, HD1A and MEM43 on RTX-induced CDC of primary CLL cells administered alone or in combination. (a) Patient cells were treated with RTX in the absence or presence of blocking anti-CD55 (HD1A), blocking anti-CD59 (MEM43) or hSCR18–20 under standard conditions. Addition of HD1A and hSCR18–20 significantly enhanced RTX-induced CDC (29% and 24%, respectively), whereas the blocking of CD59 by MEM43 showed minor improvement (10%). Combination of HD1A and hSCR18–20 resulted in significantly enhanced effects as compared with the effects of each compound individually. Survival rates were calculated according to the hiNHS control, which defined 100% survival. Error bars: s.e.m, n=20. (b) Treatment of primary CLL cells with HD1A, MEM43 or hSCR18–20 and active complement in the absence of RTX did not induce CDC (gray bars), as compared with the NHS control (white bar, n=16). (c) Improvement of RTX-induced CDC by blocking anti-CD55 (HD1A) was significant (P=0.0019) in comparison to non-blocking anti-CD55 (n=7). (d) No significant difference between the blocking anti-CD59 (MEM43) and non-blocking anti-CD59 was observed (n=6). Survival rates were calculated according to the hiNHS control, which defined 100% survival. Error bars: s.e.m.
